<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:EXEL (USA) Also Trade In: Germany UK

Exelixis Inc $ 16.76 -0.06 (-0.36%)

Volume:
1,975,246
Avg Vol (1m):
2,603,571
Market Cap $:
5.08 Bil
Enterprise Value $:
4.28 Bil
P/E (TTM):
8.19
P/B:
3.39
Warning! GuruFocus has detected 1 Severe warning sign with EXEL. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for EXEL (Exelixis) from 2000 to Oct 23 2019. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Exelixis stock (EXEL) PE ratio as of Oct 23 2019 is 8.19. More Details

Exelixis PE Ratio (TTM) Chart

EMBED

Exelixis PE Ratio (TTM) Historical Data

Total 1253
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Exelixis PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2019-10-238.2 2019-08-2110.5
2019-10-228.2 2019-08-2010.6
2019-10-218.2 2019-08-1911.1
2019-10-188.0 2019-08-1610.6
2019-10-178.3 2019-08-159.7
2019-10-168.2 2019-08-149.7
2019-10-158.2 2019-08-139.9
2019-10-148.0 2019-08-129.6
2019-10-118.1 2019-08-0910.1
2019-10-108.1 2019-08-0810.2
2019-10-097.9 2019-08-0710.0
2019-10-088.1 2019-08-069.9
2019-10-078.2 2019-08-059.6
2019-10-048.3 2019-08-029.7
2019-10-038.8 2019-08-0110.0
2019-10-028.8 2019-07-3110.4
2019-10-018.7 2019-07-3010.3
2019-09-308.6 2019-07-2910.3
2019-09-278.8 2019-07-2610.2
2019-09-268.9 2019-07-2510.1
2019-09-259.2 2019-07-2410.1
2019-09-249.0 2019-07-2310.2
2019-09-239.4 2019-07-2210.5
2019-09-209.5 2019-07-1910.4
2019-09-199.6 2019-07-1810.8
2019-09-189.4 2019-07-1710.6
2019-09-179.5 2019-07-1610.5
2019-09-169.4 2019-07-1510.5
2019-09-139.4 2019-07-1210.2
2019-09-129.4 2019-07-1110.2
2019-09-119.5 2019-07-1010.2
2019-09-109.4 2019-07-0910.2
2019-09-099.3 2019-07-0810.0
2019-09-069.4 2019-07-0510.3
2019-09-059.5 2019-07-0410.4
2019-09-049.4 2019-07-0310.4
2019-09-039.7 2019-07-0210.3
2019-09-029.7 2019-07-0110.5
2019-08-309.7 2019-06-2810.4
2019-08-299.5 2019-06-2710.3
2019-08-289.4 2019-06-2610.0
2019-08-279.3 2019-06-2510.2
2019-08-269.6 2019-06-2410.0
2019-08-239.8 2019-06-2110.3
2019-08-2210.1 2019-06-2010.2

Exelixis PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Biotechnology » Biotechnology NAICS : 541714 NAICS : 8731
Traded in other countries EX9.Germany 0IJO.UK EXEL.USA
Address 1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer as Cometriq and advanced renal cell carcinoma, or kidney cancer, as Cabometyx. Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma. The company has partnerships with larger pharmaceutical and biotech firms to develop its pipeline, including Bristol, Sanofi, and Merck.